Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir [Paxlovid] in Patients with COVID-19

Sonu Abraham et al.

Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe disease. Patients with cardiovascular risk factors and cardiovascular disease are at a high risk of developing adverse events from COVID-19 and as a result have a higher likelihood of receiving NMVr. Ritonavir, the pharmaceutical enhancer used in NMVr, is an inhibitor of the enzymes of CYP450 pathway, particularly CYP3A4 and to a lesser degree CYP2D6, and affects the P-glycoprotein pump. Co-administration of NMVr with medications commonly used to manage cardiovascular conditions can potentially cause significant drug-drug interactions and may lead to severe adverse effects. It is crucial to be aware of such interactions and take appropriate measures to avoid them. In this review, we discuss potential drug-drug interactions between NMVr and commonly used cardiovascular medications based on their pharmacokinetics and pharmacodynamic properties.

… Figure 1: Drug-Drug Interactions of Cardiovascular Medications with Nirmatrelvir-Ritonavir

Latest articles

Madhava Setty Primum non nocere, “first and foremost, I will do no...
Emily Kopp and Karolina Corin A team of Western virologists could face...
privacyisyourright.ca Using the declaration of a pandemic as an excuse, the CPSO...
Aric Cox Many of you have been on protocol, after protocol, after...
Jeffrey Jaxen Talking to the news host, German Health Minister Karl Lauterbach...
Merinda Teller Over the past six decades, solid organ transplantation has gone...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!